Skip to content

Association of beta-blocker therapy with outcomes after ST-segment elevation myocardial infarction stratified by GRACE risk score: A nationwide registry analysis.

Oct 2026 · Atherosclerosis · Vol 422, pp. 121919 · 0 citations · 21 references
Medicine

Abstract

Background

Associations between beta-blocker use following ST-segment elevation myocardial infarction (STEMI) and clinical outcomes remain uncertain in the contemporary era of near-universal early revascularization and drug-eluting stent (DES) implantation, particularly for patients with preserved left ventricular function. We sought to determine whether associations between beta-blocker use at discharge and outcomes varied across Global Registry of Acute Coronary Events (GRACE) risk strata.

Methods

We performed a post-hoc analysis of 11,866 STEMI survivors from two prospective nationwide Korean registries who underwent successful percutaneous coronary intervention (PCI) with second-generation DES. Patients were categorized by beta-blocker prescription at discharge. The primary endpoint was all-cause mortality at one year; secondary outcomes included major adverse cardiac events (MACE). Propensity-score matching and inverse-probability treatment weighting were employed to mitigate confounding. Variation in associations was examined across the continuous GRACE risk spectrum, categorized into low-risk (GRACE <85), intermediate-risk (GRACE 85-179), and high-risk (GRACE ≥180) strata.

Results

Beta-blockers were prescribed to 83.8% of the cohort. After propensity matching, beta-blocker use was associated with lower one-year all-cause mortality (2.7% vs. 4.2%; hazard ratio [HR] 0.63; 95% confidence interval [CI] 0.44-0.91) and MACE (6.0% vs. 8.3%; HR 0.71; 95% CI 0.55-0.92). These associations attenuated by three years. The GRACE 2.0 score exhibited robust discrimination for mortality (AUC = 0.79; 95% CI: 0.76-0.82). Continuous interaction analyses showed small model-estimated absolute risk differences in low-risk patients (GRACE <85), whereas the largest model-estimated absolute risk difference was observed in intermediate-risk individuals (GRACE 85-179).

Conclusions

Among STEMI survivors treated with contemporary PCI, associations between beta-blocker use at discharge and outcomes varied according to baseline GRACE risk. No statistically significant association was observed in low-risk individuals (GRACE <85), whereas the association with lower mortality was most evident in the intermediate-risk group (GRACE 85-179). These hypothesis-generating findings warrant evaluation in randomized trials before being used to guide treatment decisions.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.